Treatment of Klebsiella pneumoniae Infections

Introduction to Treatment Guidelines

• The American College of Cardiology is not applicable here, however, the Infectious Diseases Society of America recommends ceftazidime-avibactam as first-line treatment for carbapenem-resistant Klebsiella pneumoniae strains, with combination therapy recommended for severe infections 1

Treatment Based on Resistance Pattern

• For ESBL-producing K. pneumoniae, carbapenems remain effective but should be used judiciously, and β-lactam/β-lactamase inhibitor combinations may be considered as carbapenem-sparing alternatives 3
• Ceftolozane/tazobactam is another option for ESBL-producing strains 3

Carbapenem-Resistant K. pneumoniae (CRKP) Treatment

• Ceftazidime-avibactam is recommended as first-line therapy for KPC-producing strains with clinical success rates of 60-80% 1
• For MBL-producing strains, ceftazidime-avibactam plus aztreonam is recommended with 70-90% efficacy 1
• Imipenem-relebactam or cefiderocol are alternatives when first-line options are unavailable 1
• Polymyxins (colistin) may be used in combination therapy for highly resistant strains 4

Combination Therapy for Severe CRKP Infections

• Combination therapy with two or more in vitro active antibiotics is recommended for severe CRKP infections, particularly in critically ill patients 4
• Combination therapy is associated with lower 14-day mortality compared to monotherapy in bloodstream infections and non-bacteremic infections 4
• For polymyxin or tigecycline-based regimens, adding a companion drug is advisable 5

Special Considerations for Highly Resistant Strains

• Double-carbapenem therapy may be considered in limited options, though evidence is insufficient 5
• High-dose extended-infusion meropenem in combination with polymyxin may be effective even with higher MICs (≤16 mg/L) 5

Therapeutic Drug Monitoring (TDM)

• TDM is recommended when using polymyxins, aminoglycosides, or carbapenems for CRKP infections 6
• TDM is particularly important in critically ill patients with CRKP infections, patients with renal dysfunction or hyperfunction, and when treating difficult-to-reach infection sites 6

Antimicrobial Stewardship Considerations

• Carbapenem-sparing strategies are recommended, particularly in settings with high incidence of CRKP 3
• Novel β-lactam/β-lactamase inhibitor combinations are valuable for preserving carbapenems 3
• Limiting extended use of carbapenems can reduce carbapenem resistance by 20-30% 1

Pitfalls and Caveats

• Resistance to ceftazidime-avibactam in KPC-producing isolates has been reported (0-12.8%) 1
• Mutations in the blaKPC-3 gene can confer resistance to ceftazidime-avibactam 1
• Tigecycline performs poorly in bacteremic patients and should not be used as first-line therapy in patients with bacteremia 3
• Source control is essential alongside appropriate antimicrobial therapy 1